Lyell Immunopharma Announces Pricing of Initial Public Offering
June 16 2021 - 9:49PM
Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell
reprogramming company dedicated to the mastery of T cells to cure
patients with solid tumors, today announced the pricing of its
initial public offering of 25,000,000 shares of its common stock at
a public offering price of $17.00 per share. All of the shares of
common stock are being offered by Lyell. The gross proceeds from
the offering, before deducting underwriting discounts and
commissions and other offering expenses payable by Lyell, are
expected to be approximately $425 million. Lyell’s common stock is
expected to begin trading on the Nasdaq Global Select Market on
June 17, 2021 under the ticker symbol “LYEL.” The offering is
expected to close on June 21, 2021, subject to the satisfaction of
customary closing conditions. In addition, Lyell has granted the
underwriters a 30-day option to purchase up to an additional
3,750,000 shares of its common stock at the initial public offering
price, less the underwriting discounts and commissions.
Goldman Sachs & Co. LLC, BofA Securities,
J.P. Morgan and Morgan Stanley are acting as joint book-running
managers for the offering.
A registration statement relating to the shares
being sold in this offering was filed with the Securities and
Exchange Commission and became effective on June 16, 2021. The
offering is being made only by means of a prospectus. Copies of the
final prospectus, when available, may be obtained from: Goldman
Sachs & Co. LLC, Attention: Prospectus Department, 200 West
Street, New York, NY 10282, by telephone at (866) 471-2526, or by
email at prospectus-ny@ny.email.gs.com; BofA Securities,
NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC
28255-0001, Attention: Prospectus Department, or by email at
dg.prospectus_requests@bofa.com; J.P. Morgan Securities LLC,
Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, by email at prospectus-eq_fi@jpmorgan.com, or
by telephone at (866) 803-9204; or Morgan Stanley, Attention:
Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY
10014, or by email at prospectus@morganstanley.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Lyell Immunopharma,
Inc.
Lyell is a T cell reprogramming company
dedicated to the mastery of T cells to cure patients with solid
tumors. The Company focuses on addressing what it believes are the
primary barriers that limit consistent, reliable and curative
responses with adoptive T cell therapy: T cell exhaustion and loss
of durable stemness, which includes proliferative capacity, ability
to self-renew and ability to differentiate and eliminate solid
tumors. Lyell is applying its proprietary ex vivo genetic and
epigenetic reprogramming technology platforms, Gen-R and Epi-R, to
address these barriers in order to develop new medicines with
improved, durable, and potentially curative clinical outcomes.
Lyell is based in South San Francisco, Seattle and Bothell,
Washington.
Contacts:
Ellen RoseVice President,
Communicationserose@lyell.com
Heather TurnerHead of Investor
RelationsIR@lyell.com
Lyell Immunopharma (NASDAQ:LYEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lyell Immunopharma (NASDAQ:LYEL)
Historical Stock Chart
From Sep 2023 to Sep 2024